- Valsartan/amlodipine uses
- Valsartan/amlodipine 5 mg
- Valsartan/amlodipine dosage
- Valsartan/amlodipine dosage forms
- Valsartan/amlodipine drug
Dosing & Uses
Dosage Forms & Strengths
Initiate with 5 mg/160 mg PO qDay OR
Substitute for individually titrated components
May increase dose after at least 2 weeks, not to exceed 10 mg/day amlodipine and 320 mg/day valsartan
May be adminsitered concomitantly with other antihypertensive agents
- Mild or moderate (CrCl >30 mL/min): Dose adjustment not necessary
- Severe (CrCl <30 mL/min): Not studied
- Not recommended for initial therapy; amlodipine 2.5 mg is not an available strength with available dosage forms for this drug combination
- Amlodipine: Exposure is increased with hepatic insufficiency, consider decreasing dose
- Valsartan: Exposure increased with mild-to-moderate hepatic insufficiency does not require dosage adjustment; unknown for severe hepatic impairment
Safety and efficacy not established
Not recommended for initial therapy; amlodipine 2.5 mg is not an available strength with available dosage forms for this drug combination
Base initial dose on 2.5 mg of amlodipine PO qDay
No overall difference in the efficacy or safety of valsartan has been observed, but greater sensitivity of some older individuals cannot be ruled out
Pregnancy & Lactation
Pregnancy Category: C (1st trimester); D (2nd & 3rd trimesters). During the second and third trimesters of pregnancy, these drugs have been associated with fetal injury that includes hypotension, neonatal skull hypoplasia, anuria, reversible or irreversible renal failure, and death.
Lactation: discontinue drug or do not nurse
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.